FAQ on Quantum BioPharma Ltd.'s Opposition to Motion to Dismiss in $700 Million Market Manipulation Lawsuit

What is Quantum BioPharma Ltd. alleging in its lawsuit?

Quantum BioPharma alleges that CIBC World Markets and RBC Dominion Securities, among others, engaged in market manipulation through ‘spoofing’ between January 1, 2020, and August 15, 2024, violating federal securities laws and artificially depressing its stock price.

How much in damages is Quantum BioPharma seeking?

Quantum BioPharma is seeking more than $700 million in damages.

Who is representing Quantum BioPharma in this lawsuit?

The case is being pursued on a contingency basis by Christian Attar and Freedman Normand Friedland LLP.

What is ‘spoofing’ in the context of this lawsuit?

Spoofing refers to the alleged practice of placing fake orders to buy or sell stocks to create a false impression of demand or supply, thereby manipulating the market price.

What is the significance of Quantum BioPharma’s stock price mentioned in the lawsuit?

Quantum BioPharma’s stock once traded above $460 per share before the alleged market manipulation artificially depressed its price.

Is Quantum BioPharma open to resolving the lawsuit outside of court?

Yes, Quantum BioPharma remains open to a potential resolution and believes additional banks or brokers may be involved.

What does Quantum BioPharma Ltd. do?

Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, alcohol misuse disorders, and maintains a portfolio of strategic investments.

Where can investors find the latest news and updates about Quantum BioPharma Ltd.?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

What is InvestorWire’s role in this context?

InvestorWire is a specialized communications platform that provides advanced wire-grade press release syndication for private and public companies, including Quantum BioPharma Ltd.